Search Results for “EC” – Page 587 – media

How an active social life could lower diabetes risk

New European research has found that a good social life could lower the risk of developing type 2 diabetes and pre-diabetes.
- Source: msn
- 519
- December 21, 2017
Researches social life type 2 diabetes
4 Tips for Purchasing Medical Devices

Over the past decade, the medical device industry has seen a boom in development and innovative ideas. With this innovation came a rise in the costs of medical device products which presents new challenges to buyers. With this in mind, we have compiled a list of 4 tips that could help you in this decision making process.
- Source: Ddu
- 797
- December 21, 2017
Ddu College medical device
Nanoparticle-Based Imaging of Metastasis Throughout Body

Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go
- Source: medgadget
- 859
- December 20, 2017
breast cancer MRI Researches tumor
Surgery of the future

First of all, a 3D model of the patient was been created before surgery, combining images previously acquired via an MRI scanner, or radiography. On the day of the operation, a 3D image was (virtually) projected on the patient, and helped Dr Grégory in any of his movements and decision making.
- Source: leyton
- 701
- December 20, 2017
Researches Surgery of the future
Silencing ‘junk’ gene could halt tumor growth

The gene is in an area of the genome that does not contain instructions for making proteins. At one time, it was thought that this non-coding area was just irrelevant "junk."
- Source: Medicalnewstoday
- 527
- December 20, 2017
cancer Researches tumor
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy

Spark Therapeutics $ONCE has scored an historic FDA approval of Luxturna, the world’s first such AAV-delivered gene therapy designed to cure a rare eye disease triggered by a genetic mutation. The drug is OK’d for RPE65 mutation linked retinal dystrophy. The treatment uses a viral vector to insert the correct copy of a gene retinal cells need to create a protein that turns light into electric signals which can restore vision lost to the disease. As with the earlier pioneering approval of the world’s first CAR-T, FDA commissioner Scott Gottlieb did the honors in recognizing the importance of this approval. And he says the agency will make sure that the regulatory path is straight and clear for the rest of the field looking to following Spark’s footsteps. “We’re at a turning point when it comes to this novel form of therapy and at the FDA, we’re focused on establishing ...
- Source: drugdu
- 751
- December 20, 2017
FDA genetic mutation. Luxturna New Approvals rare eye disease
Ultragenyx Sells Priority Review Voucher for $130 million

“The sale of the PRV provides us with an important source of non-dilutive capital to help advance our pipeline of rare and ultra-rare therapies, and accelerates the availability of these potential therapies to patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- Source: finance.yahoo
- 710
- December 20, 2017
FDA Market Views Novartis PRV
Are You Doing A Good Job In Bed?

A lack of sleep has been linked to high blood pressure and other cardiovascular ailments, mental health conditions like depression and weight-related issues such as obesity and diabetes.
- Source: msn
- 651
- December 20, 2017
diabetes high blood pressure obesity Researches sleep
Artificial Intelligence Could Help in Breast Cancer Diagnosis

Researchers say AI procedure was successful in detecting the spread of breast cancer. It’s the latest artificial intelligence innovation in the medical world.
- Source: healthline
- 640
- December 19, 2017
Artificial Intelligence breast cancer Researches
US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO® (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases, in the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 (L858R) substitution mutations). The FDA has granted TAGRISSO Priority Review status, and previously granted Breakthrough Therapy Designation for TAGRISSO in the 1st-line treatment of patients with metastatic EGFR mutation-positive (EGFRm) NSCLC.
- Source: finance.yahoo
- 606
- December 19, 2017
AstraZeneca CNS FDA New Approvals NSCLC TAGRISSO®

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.